Subsidiary YKYY013 injection of Youcare Pharmaceutical Group (688658.SH) approved for clinical trials.

Youcare Pharmaceutical Group (688658.SH) announced that its subsidiaries, Beijing Yekang Kechuang Pharmaceutical Technology Co., Ltd. (referred to as "Yekang Kechuang") and Hangzhou Tianlong Pharmaceutical Co., Ltd. (referred to as "Hangzhou Tianlong"), have recently obtained the Drug Clinical Trial Approval Notification issued by the National Medical Products Administration (NMPA) for YKYY013 injection to treat chronic hepatitis B virus infection. The company will conduct Phase I clinical trials for this product. YKYY013 injection is a chemically synthesized dual-chain siRNA drug developed independently by Yekang Kechuang and Hangzhou Tianlong, coupling with N-acetylgalactosamine (GalNAc) ligand. It effectively silences messenger RNA (mRNA) transcribed from HBV genome through RNA interference, thereby inhibiting the production of HBV pathogenic proteins, suppressing HBV replication, and creating conditions for host immune reconstruction, ultimately achieving functional cure for hepatitis B. It is clinically intended for the treatment of chronic hepatitis B virus infection.